Skip to content
Pierre Country
    • Homepage
Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions

Author: Mapi Pharma

Posted Date:

June 1, 2026
  • Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions

    Mapi Pharma
    June 1, 2026
  • Mapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for Aseptic and Long-Acting Generic and innovative Injectables

    Mapi Pharma
    May 4, 2026
  • Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) at AAN 2026

    Mapi Pharma
    April 16, 2026
  • Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

    Mapi Pharma
    February 19, 2026
  • Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026

    Mapi Pharma
    February 3, 2026